Ionis

News

Race for hepatitis B drug intensifies as Antios raises $96m ...

Antios has raised $96 million in Series B financing to support the ongoing phase 2 development of its hepatitis B drug candidate, ATI-2173.

News

Roche stops dosing in trial of Huntington's disease hopeful ...

Roche has stopped dosing in a phase 3 trial of tominersen, a potential Huntington’s disease (HD) drug developed with Ionis, after a pre-planned review by independent experts.

News

The diagnosis Hepatitis written on a clipboard

Ionis deal delivers for GSK as HBV drug hits the mark in pha...

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widesprea

News

Pfizer inks deal with Ionis and Akcea for potential blockbus...

Pfizer has signed a deal with Ionis’ affiliate Akcea Therapeutics, to develop a potential blockbuster antisense therapy to treat patients with certain cardiovascular and metabolic diseases

News

Akcea/Ionis' rare disease drug Waylivra set for EU market af...

European regulators have recommended a licence for Akcea and Ionis’ ultra-rare disease drug Waylivra, a therapy that the FDA rejected for the US market last year.

News

Novartis licenses lipoprotein-lowering CVD drug

Excited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment to reduce the risk of cardiovascular disease in people living with elev

Race for hepatitis B drug intensifies as Antios raises $96m ...

Roche stops dosing in trial of Huntington's disease hopeful ...

Ionis deal delivers for GSK as HBV drug hits the mark in pha...

Pfizer inks deal with Ionis and Akcea for potential blockbus...

Akcea/Ionis' rare disease drug Waylivra set for EU market af...

Novartis licenses lipoprotein-lowering CVD drug

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Ionis

Editor's Picks